trending Market Intelligence /marketintelligence/en/news-insights/trending/MQ0GY0voztsxJOYooXKQ-A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Mallinckrodt suspends specialty generics spinoff plans

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Mallinckrodt suspends specialty generics spinoff plans

Mallinckrodt PLC is suspending plans to spin off its specialty generics and active pharmaceuticals ingredients business, citing current market conditions and uncertainties around the opioid litigation against the company.

Mallinckrodt is among a number of drugmakers including Johnson & Johnson and Allergan PLC that are facing litigation in the U.S. for allegedly engaging in marketing practices that contributed to the ongoing opioid epidemic.

The company said it is considering a "range of options" that would lead to the separation of the specialty generics business.

Staines-Upon-Thames, U.K.-based Mallinckrodt said in May that it would list the unit on the New York Stock Exchange.